Introduction
Intracranial hemorrhage (ICH) is associated with high mortality and morbidity. 1 Men are at greater risk as are the elderly and those with hypertension. Increasing evidence has suggested that serum cholesterol is inversely associated with the risk of ICH. [2] [3] Low cholesterol may promote arterial muscle necrosis, 4 and endothelial susceptibility to microaneurysm and thus, ICH. 5 HMG-CoA reductase inhibitors (statins) are widely used to lower serum cholesterol for the primary and secondary prevention of cardiovascular disease. Concerns that higher dosage statin therapy increases the risk of ICH particularly for those with a history of cerebrovascular events have been reported. [6] [7] In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, patients with previous ischemic strokes randomized to atorvastatin at 80 mg/day had an increased incidence of ICH. [8] [9] Similarly, in the Heart Protection Study (HPS), the simvastatin at 40 mg/day group had an increased incidence of ICH among those with a history of cerebrovascular disease. 10 However, subsequent meta-analyses failed to show an association between statins and an increase in ICH. [11] [12] These inconsistencies might arise from differences in sample size, study design, enrolled populations, therapeutic definitions, target outcomes, and comparison groups. 11, [13] [14] The revised cholesterol-treatment guidelines issued by the American Heart Association and the American College of Cardiology in 2013 lowered the criteria for those who would qualify for statin treatment to prevent heart disease thus, increasing dramatically the eligible treatment population. 15 Since ICH is more prevalent among Asians, the risk-benefit profile for statin use in this population is of particular interest especially among those without cerebral vascular histories. [16] [17] [18] [19] Previous observational studies of statin usage may also have been biased events have been reported. [6] [7] In the Stroke Prevention by Aggressive Reduction i i in n Ch Ch Chol ol oles es este te tero ro r l l Levels (SPARCL) trial, patients with previous ischemic strokes randomized to atorvastatin at 80 mg mg g/d /d /day ay ay h h had ad ad a a an in in ncr cr cre eased incidence of ICH. [8] [9] Sim im imil l larly, in the Hea ea e rt P P Pro ro rot tection Study (HPS), the i i im mv mvastatin at t 4 4 40 0 0 m mg mg/d /d /day ay y g g gro ro roup u up h had ad ad a an n n i in ncre ea eas sed in incid de den nc nce e o of f I ICH CH CH a am mo on ng ng t t tho ho hose se w w wit it ith h h a a a hi hi hist sto o ory y y of ce ere re rebr br brov ov o as as scu cu cula lar r di dise seas ase. e. 10 0 H How ow o ev ev ever er er, , su su ubs bs bseq eq eque ue ent nt n m m me et eta-a--an n nal al aly ys yse e es s s f fa fail il led ed ed t t to sh show ow ow a a an n as as ass soc c cia at atio ion n n between stat tin in ns s an an nd d d an an n i i inc ncre re reas as a e e in in in I ICH CH CH. 11 11 11-12 12 12 T T The he hese se se i inc nc n on n nsi si sist st sten en enci ci cies es e m m mig ig ght ht ht a a ari ri rise se f f fro ro rom m m di di d fferences i in n by guest on September 14, 2016 http://circ.ahajournals.org/ Downloaded from 4 (confounding by indication) because the nonusers with lower serum cholesterol values would have had higher baseline ICH risk. Thus, the current study was designed to address these potential shortcomings by analyzing the risk of ICH in a very large Asian population (Taiwan National Health Insurance Database). Comparisons were made for cumulative statin usage among all statin initiators without prior history of stroke. The hazards were further evaluated among known subgroups with increased risk of ICH.
Methods

Data source
The study protocol was approved by the National Taiwan 
Study population
From the source population, all adult patients more than 20 years of age were identified who initiated statins, including lovastatin, pravastatin, fluvastatin, simvastatin, atorvastatin, and rosuvastatin between January 1, 2005 and December 31, 2009. Initiation was defined as being free from any statin therapy for 12 months prior to the first prescription (index date). Subjects were excluded if they were: 1) 100 years of age or older, 2) not continuously covered by
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had a prior history of ischemic stroke or ICH 24 months prior to the index date (Figure 1 ).
Cumulative exposure of statins
Drug usage information was obtained from the outpatient pharmacy prescription database, including prescribed drug types, dosage, date of prescription, supply days, and total number of pills dispensed. Since patients with hypercholesterolemia might discontinue statin or restart lipidlowering drug therapy, the analyses assumed that patients' exposure to each studied drug contributed both cumulatively and continuously to their long-term risk of ICH.
Defined daily dose (DDD) is the assumed average maintenance dose per day for a drug used for its main indication in adults. 20 To investigate the effect of dose, the cumulative use of statins was calculated as total prescribed DDD (i.e., the same as total dispensed DDD under this system). Exposure to cumulative statin dosage was then treated as a time-varying variable in the analysis. At the time when an ICH event occurred, the cumulative statin dosage was recorded as a total of DDD from drug initiation to the day before the hospitalization. For those who were still at risk (event free and uncensored) in the cohort, the cumulative doses were recorded and ranked at each event time. Participants were then classified into mutually exclusive dosage categories based on the quartiles of cumulative dosage distribution of the "risk set" at that time point. 21 As time passed and the statin dosage accumulated during the follow-up period, a participant could enter either a higher or a lower quartile.
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Ascertainment of intracranial hemorrhage
The outcome of interest was defined as a patient receiving a hospital diagnosis of ICH (ICD-9-CM codes 430, 431, 432). A systematic review of the algorithms using administrative claims Defined daily dose (DDD) is the assumed average maintenance dose per r d d day y y f f for or o a a a d d dru ru r g g used for its main indication in adults. 20 To investigate the effect of dose, the cumulative use of t tat at tin in ins s s wa wa was s s ca ca alcul ul ula at ated e as total prescribed DDD (i (i i.e .e . ., , the same as t tot o o al d d dis is isp p pensed DDD under this y yst t tem e ). Expos osu ur re e to o c cum um mul ula at ati iv ive e st st s a at atin n n d d dosa a age e e wa a as the en en t tre reat ted ed a as s a a ti ti ime me me-v va ar ary yi ying ng g v var ar a ia ia iabl l le e in n in t t th he an nal al alys ys ysis is i . . At At At t t th he he t t tim im me e wh wh when en an n n IC IC CH H H e ev eve en ent t t oc oc occu cu c rr rr rre ed d d, t t the he e c cum um umul ulat at ativ iv ve e st st stat ati i in d dos os sag ag age e e wa wa was s s re e eco o ord rde e ed a as s a total of DDD DD D f f fro ro om m m dr dr d ug ug u i i ini ni niti t t at at tio io ion n to to t t t the he he d d day ay ay b b bef ef fo o ore re e t the he e h h hos os ospi pi pita ta tali l l za za ati ti ion on on. . Fo Fo For r th th thos os ose e e wh wh w o were stil l l 6 data to identify patients with intracranial bleedings showed that the positive predictive values for inpatient codes of subarachnoid hemorrhage (SAH) (ICD-9 codes 430) and intracerebral hemorrhage (ICD-9 codes 431) ranged from 80% to 98%. 24 The following additional criteria were required to increase the positive predictive value further: 1) a record of brain imaging (CT or MRI) during hospitalization, 2) issued certificate for stroke, and 3) records of stroke related rehabilitation, consultation, or therapy during hospitalization. 25 The Bureau of Taiwan NHI issues certificates to patients who suffer from major illness including acute ischemic or hemorrhagic stroke.
To evaluate the accuracy of the resulting algorithm for identifying patients with ICH, a validation study was conducted by randomly sampling records of 226 hospitalized patients at one medical center with ICD-9-CM codes of 430, 431, and 432. Their medical records were then reviewed by a physician (YCL). The positive predictive value was 93.8% using these criteria.
Patients were followed from the index date to the earliest outcome occurrence, death, disenrollment from the national health insurance, or study termination December 31, 2010.
Covariate ascertainment and adjustment
Inpatient and outpatient files from the year prior to the index date, were used to ascertain comorbidities including diabetes mellitus, hypertension, cardiovascular, peripheral vascular, liver, lung, kidney, musculoskeletal, gastrointestinal, neurological, oncologic and psychiatric disorders (using ICD-9-CM codes provided in Supplementary Table 1 ). In addition, inpatient and outpatient prescription records were also analyzed (using anatomical therapeutic chemical [ATC] codes as provided in Supplementary Table 1) . Demographic data were recorded regarding age, sex, and resource utilization (number of outpatient visits and hospitalizations) 12 months prior to the index date.
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P Pati i ien e ts were fo foll l l o ow owed ed e f f fro ro om m m th th the e in in nd de dex x d da ate to to the e ea arli i ies es st t o ou ut tc com om me e e oc occ cu ur rr ren en nce ce e, , de de eat at ath, h, h, di dise se senr nr nrol ol o lm lmen en ent t fr from om om t th he e n n nat atio ona na n l l l he he heal al a th th ins ns nsu u ur r ranc nc nce, e, , o or r r st t tud ud dy y y t te term rm rmin in nat at tio io ion n D De Dece ce emb mb mber er 3 31 1 1, Due to the large number of covariates, a summary measure or "disease risk score" (DRS) was computed to handle any baseline imbalance among all statin initiators. The DRS, a valuable tool to balance important covariates across treatment groups, has been widely used to advantage in pharmacoepidemiological research to consolidate outcomes in studies with multiple comparison groups. [27] [28] The concept that a study-specific disease risk score can control confounding and improve modeling strategies has been discussed in detail elsewhere. 29-30 A twostep approach was used for confounder adjustment. In the first-step, development of a nonparsimonious logistic regression model including covariates of age, sex, initiation year, underlying diseases, and concomitant medications use in the 12 months prior to the index date (as listed in Table 1 ) was used to calculate the predicted probability (DRS) of ICH occurrence for each participant. In the subsequent step, the main analysis, the estimated DRS was used as a he lowest cumulative dosage category as the reference group. 26 Therefore, the ha ha aza a ard rd d r r rat at atio io io between quartiles is a pooled risk estimate for those who ranked high and who ranked low across al ll l di di diff ff ffe er eren en nt t t ti ti time e e p p po oints.
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Several sensitivity analyses were conducted by 1) excluding SAH as an outcome because its etiology may be due to ruptured cerebral aneurysm or arteriovenous malformation and unrelated to statin mediated serum cholesterol changes; 2) not requiring "a record of rehabilitation, consultation, or therapy during hospitalization" as an outcome definition to avoid inadvertently excluding patients with either the most severe/fatal ICH, or those with mild bleeding not requiring rehabilitation; 3) adjusting for Charlson's index, 31 , 4) adjusting for the clinically most relevant variables such as age, sex, year, prior history of ischemic or hemorrhagic stroke, hypertension, cardiovascular disease, chronic kidney disease, and aspirin use (i.e., traditional multivariable regression), and 5) excluding study participants with atrial fibrillation (AF) because of the risk of hemorrhagic transformation from embolic stroke which might confound study results. Furthermore, three auxiliary analyses were designed to evaluate the effects of different disease risk scores. The sixth sensitivity analysis was performed by using statistically significant variables to construct a different DRS as a single covariate, aiming to demonstrate whether there would be a difference between parsimonious and non-parsimonious models. The seventh sensitivity analysis used a non-parsimonious Cox model, in contrast to logistic regression model in the main analysis, to obtain a similar type of score. The eighth sensitivity analysis was the same as sensitivity analysis 7 except that the variable "initiation year" was not used in the calculation of DRS.
Furthermore, stratified analyses were performed to evaluate the risk of ICH associated with high cumulative statin use in several subgroups. Participants were further stratified according to advanced age ( 70 years), sex (men, women), and the presence of hypertension.
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Patients were classified as hypertensive if they had at least one hospital admission with a diagnostic code of hypertension (ICD9-CM code 401) or two or more outpatient visits with a hypertension diagnostic code. 32-33 Statistical tests for interaction were conducted.
Statins were further classified as high LDL-lowering efficacy (atorvastatin, rosuvastatin) and low LDL-lowering efficacy (lovastatin, fluvastatin, pravastatin, simvastatin). 34 ICH risks associated with these statin subtypes were then explored. To evaluate whether death serves as a competing risk to ICH and thus, could bias study results, hazard ratios of death for each cumulative statin dosage category were calculated. This was conducted to evaluate whether participants with higher cumulative statin use had different survivals and thus, might influence their probability of developing ICH. In addition, the relationship of cumulative statin use with ischemic stroke was also examined.
A two-sided P value < 0.05 was considered to be statistically significant. All statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC).
Results
A total of 1,096,547 statin initiators were included in the analysis (Figure 1 ). Among these participants, hypertension, AF, heart failure, seizure, and chronic kidney disease were associated with a significantly increased risk of ICH ( Table 1 ). In addition, use of calcium channel blockers, diuretics, insulin, non-aspirin anti-platelet agents, warfarin, and digoxin were also associated with a higher risk of ICH. In contrast, estrogen use was associated with a lower risk of ICH ( Table 1) .
Among study participants, a total of 2,368 ICH cases occurred during an average followup of 3.3 years. The crude incidence rate was 1.83 (95% CI: 1.75 to 1.90) per 1,000,000 personheir probability of developing ICH. In addition, the relationship of cumulative st st tat tin in i u u use e se w w wit it ith h schemic stroke was also examined.
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days. Generally, there was no statistically significant association between cumulative statin dosage and ICH. The crude HR comparing the highest quartile to the lowest one was 1.14 (95% CI: 1.01-1.29), but reduced to 1.06 (95% CI: 0.94-1.19) after adjusting for the disease risk score.
The hazard ratios associated with other cumulative dosage categories were all very near 1.00
( Table 2) .
Similar results were found in several sensitivity analyses using different outcome definitions, using Charlson's index to control for baseline differences, using multivariable regression analysis including the clinically most relevant variables, and excluding all participants with atrial fibrillation (Sensitivity analyses 1/2, 3, 4, and 5 in Table 3 ). Sensitivity analysis 6, adjusted by a parsimonious model derived DRS, produced HRs consistent with the finding of no increased ICH risk associated with statin use. Sensitivity analyses 7 and 8 in which DRSs were obtained from Cox regression models provided similar results to the main analysis ( Table 3 ).
The persistence of these results suggests the study findings are robust.
An additional analysis demonstrated a dose-response relationship between cumulative dose of statins use and a reduced mortality risk (Supplementary Table 2 ). This protective effect of statins precludes the possibility of death as a competing risk to ICH. Similarly, there was an inverse relationship between cumulative statin dosage and the incidence of ischemic stroke (Supplementary Table 2 ).
Participants were further stratified according to age (< 70, 70 years), sex (men, women), and the presence or absence of hypertension for further subgroup analyses ( Table 4) .
No statistically significant association with statin use was found in the two age subgroups and in either men or women. Patients with and without hypertension had different demographic and risk Table 3 ). The subjects in the hypertensive subgroup had more coadjusted by a parsimonious model derived DRS, produced HRs consistent with t th he he f f fin in nd di ding ng ng o o of f no n ncreased ICH risk associated with statin use. Sensitivity analyses 7 and 8 in which DRSs were ob bta ta ain in ined ed ed f f fro ro rom m m Co Co ox x x r regression models provided si si sim milar results to t t the h m m mai ai ain n analysis ( Table 3) .
variables (Supplementary
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An An a a add d ddit iti i ion na nal l an an nal aly ysis is is d d dem em emo on onst st tra a ate te ted d d a a do do d s s se--r -res es spo po ons ns nse re re rela la ati ion on onsh sh hip p p b bet et etwe we ween en n c c cum m mul l lat ativ iv ve dose of statin ns s s us us u e e e an an and d d a a a re e edu du duce ced d d mo mo mort r al al alit it ty y y ri ri r sk sk sk ( ( (Su Su Supp pp pple e eme me ment nt ntar ar ary y y Ta Ta Tabl bl ble e e 2 2 2). ). ). T T Thi hi his s s pr pr prot ot otec e e tive effect t t morbidities (such as diabetes mellitus, ischemic heart disease, arrhythmia, transient cerebral ischemia, chronic lung disease, and gout, etc.), used a variety of anti-hypertensive and oral hypoglycemic agents more frequently, and utilized more medical resources (Supplementary The analyses also stratified all study participants into high vs. low efficacy LDL-lowering statins. Higher cumulative use of the better LDL-lowering statins was not associated with a significantly increased risk of ICH, despite an adjusted HR of 1.14 (95% CI: 1.00-1.31) for those in the 3rd quartile category (Supplementary Table 4 ).
Discussion
The current study found no significant association or a dose-response relationship between stain use and an increased risk of ICH among statin initiators without prior history of stroke. The data do not support the concern that statin use might be associated with an increased risk of ICH.
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Further analyses examining the risks associated with high-and low-efficacy statins similarly did not suggest that high-efficacy statins were associated with any increased risk of ICH. A slight increase in the incidence of ICH was observed in patients without prior cerebrovascular events or hypertension, but this finding from a subgroup analysis should be interpreted with caution.
Previous studies showed that even among survivors of either acute ischemic stroke or
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Discussion
showed an increased risk of hemorrhagic stroke during high-dose atorvastatin treatment as compared to placebo. 8 The increased risk was primarily observed in their elderly, male subjects with previous hemorrhagic stroke events, and subjects with hypertension. The rates of fatal hemorrhagic stroke were not increased in the atorvastatin group compared to the placebo group. 38 On the contrary, the current study demonstrated, among the patients without prior stroke, a positive association between cumulative statin dosage and incidence of ICH only in those who were not hypertensive. Several mechanisms have been proposed to explain this slightly increased ICH incidence in this presumed low-risk group. Statins are at least mildly antithrombotic, and thus reduce thrombosis by inhibiting platelet aggregation and enhancing fibrinolysis which both could contribute to ICH. 9 Although the risk-benefit profile of statin therapy might vary among patients with different baseline atherosclerotic risks, 39 the overall benefit from statin use may well outweigh potential harms, even in the lower cardiovascular risk groups. 40 However, patients with a low cardiovascular risk profile should be informed of the slightly increased ICH risk when statins are prescribed.
The strength of the current study derives from the large nationally representative cohort compared to placebo. 8 The increased risk was primarily observed in their elderly y, , , ma ma m le le e s sub ub ubje je ject cts r with previous hemorrhagic stroke events, and subjects with hypertension. The rates of fatal he emo mo morr rr rrh ha hagi gi gic c st s ro o oke ke ke were not increased in the ator or orva va astatin group c com o o pa pa are re red d to the placebo g grou u up. p 38 On th he e co co cont ntra ra ary y y, th th the e e c cu curr rren en ent t t st tu ud dy d d dem m mon n nst t trat ted ed ed, , am am mon ong g g t th he e pa pa ati ien ents ts ts w wit ith ho hou ut ut p p pri io or or 13 of more than 1 million statin initiators. The study focused on the population without a history of stroke, a group whose ICH risk was not well evaluated previously. Cumulative statin therapy rather than users versus non-users was evaluated to avoid confounding by indication. A validated algorithm was used to define ICH, and statin exposure was ascertained by linking to the NHI pharmacy database rather than using self-reported questionnaires. Furthermore, covariates including underlying disease (especially hypertension), and medication use (especially antiplatelet and anti-coagulant agents), were considered in order to increase the comparability among statin initiators. A large listing of variables was consolidated into a single risk disease score to serve as a proxy for patient's baseline risk. Compared to conventional multivariable analyses, the single variable disease risk score increases the efficiency of the analyses when controlling for potential confounding.
Statin therapy is an accepted modality for reducing cardiovascular morbidity and even mortality. [41] [42] [43] A reduction in mortality risk and ischemic stroke was also demonstrated in the current cohort. A potential bias toward the null could have resulted from inadequately medicated statin users who died prematurely before they had a chance to develop ICH. Similarly those with higher statin use might survive longer with an extended opportunity to develop to ICH. Such an association would produce an increased risk of ICH for higher cumulative statin users but decreased risk for lowest cumulative dosage users. Since this was not observed, a formal competing risk analysis was not conducted. The protective effect of statins precludes the possibility of death as a competing risk to ICH.
The risk-benefit profile for statin use in the elderly is less clear and an increasing number of studies have been specifically designed to address this issue. [44] [45] The current analyses failed to find any differential association between patients aged > 70 years and those < 70 years. The ingle variable disease risk score increases the efficiency of the analyses when co co ont ntro r r ll ll llin in ing g g fo fo for r potential confounding.
St St Stat at atin in in the he era ra rapy p is an accepted modality fo o or r r re e educing cardiov ov vascu cu ula la lar r morbidity and even m mor rt rtality. 41-43 43 A A A r r red duc ucti t o on on i i in n mo m mort rt tal al a it it i y y ri isk a a and d d isc c ch hem mi mic c c st str r roke ke k w w wa a as als ls lso de demo mo mons nstr tr trat at ted ed ed in n n h th the e e cu urr rr rren en nt t t co coho ho hort r rt. A A A po po pote tent ntia ia i l l bi bi ia as a t t tow ow owa ar ard d d th h he e e n n null ll ll co co oul ul ld d h ha have ve ve r res es sul ul u t t ted d d fr fr f o om m i ina na ade de dequ qu qua at ate el ely y me me medi dic c cat te ted tatin users w who ho ho d d die ie ied d d pr pr prem em mat at atur u u el el ely y y be be befo fo ore re r t t the he hey y y ha ha h me medi di dica ca cati ti tion on on u us s se, it it it i i is s still possible that residual c con on o f fo founding by in ndi d d vidu du ua al al blood pressure and e eru u um m choleste tero ro ol va valu lu lues s s m m mig ig ght h ht h ha av ave e e in n nf fl luen n nce e ed the he he stu u ud dy dy r res esul ults ts s. 47 47 7 S Som om me e e re re epo po ort rts s ha ha have ve v su ug ugge ge est st ted h hat at at s s ser er erum um c c cho h hole lest ste er erol ol l c con on o ce cent nt n ra ra ati ti tion on ons s t th them em ems se selv lv ves es e w w wer e e e e as as asso so soci i iat at a e ed d w w wit it i h h h in nc ncre re eas as ased ed e n n nu u umb b ber rs rs o of f f hemorrhagic c st st stro ro r ke ke kes s. s 3 3 3, 48 48 48 U U Unf nf nfor o o tu tu tuna na n te te tely y y s ser er erum um um c c cho ho ole le l st st s er erol ol ol a a and nd nd re re rela la l te te ed d d la la labo bo bora ra rato tory ry ry v v val al alue ue u s were not t analysis, the differential effects between subgroups should be interpreted conservatively. Sixth, due to the complexity in statistical modeling and the limitation in computation power, only statin usage but not other medications was treated as a time-varying variable in the analysis. Finally, since the study was based on a homogeneous Asian population, the application of these results to other racial groups may be limited.
In conclusion, the results of this study in general support the safety of statin use in Taiwan, where the incidence of ICH is relatively high. There was no obvious association between statin use and ICH in patients without prior stroke, except for those who also had no hypertension. Future long-term follow-up studies are needed to clarify the balance between risk and benefit of statin use, especially in the low-risk subgroups in which a differential increase in ICH risk was observed.
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